- Home
- JGH vs DCTH Comparison
JGH vs DCTH Comparison
Compare JGH & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- DCTH
- Stock Information
- Founded
- JGH 2014
- DCTH 1988
- Country
- JGH United States
- DCTH United States
- Employees
- JGH N/A
- DCTH 76
- Industry
- JGH Investment Managers
- DCTH Medical/Dental Instruments
- Sector
- JGH Finance
- DCTH Health Care
- Exchange
- JGH Nasdaq
- DCTH Nasdaq
- Market Cap
- JGH 292.3M
- DCTH 426.3M
- IPO Year
- JGH N/A
- DCTH N/A
- Fundamental
- Price
- JGH $13.13
- DCTH $11.52
- Analyst Decision
- JGH
- DCTH Strong Buy
- Analyst Count
- JGH 0
- DCTH 4
- Target Price
- JGH N/A
- DCTH $24.00
- AVG Volume (30 Days)
- JGH 73.9K
- DCTH 873.0K
- Earning Date
- JGH 01-01-0001
- DCTH 08-04-2025
- Dividend Yield
- JGH 9.85%
- DCTH N/A
- EPS Growth
- JGH N/A
- DCTH N/A
- EPS
- JGH N/A
- DCTH N/A
- Revenue
- JGH N/A
- DCTH $53,850,000.00
- Revenue This Year
- JGH N/A
- DCTH $155.42
- Revenue Next Year
- JGH N/A
- DCTH $37.93
- P/E Ratio
- JGH N/A
- DCTH N/A
- Revenue Growth
- JGH N/A
- DCTH 1068.87
- 52 Week Low
- JGH $10.36
- DCTH $7.17
- 52 Week High
- JGH $12.85
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- JGH 71.02
- DCTH 32.83
- Support Level
- JGH $13.03
- DCTH $12.11
- Resistance Level
- JGH $13.23
- DCTH $14.15
- Average True Range (ATR)
- JGH 0.09
- DCTH 0.57
- MACD
- JGH 0.03
- DCTH -0.16
- Stochastic Oscillator
- JGH 85.71
- DCTH 9.67
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.